logo
Sly Stone died after prolonged battle with COPD. The condition can be debilitating.

Sly Stone died after prolonged battle with COPD. The condition can be debilitating.

USA Todaya day ago

Sly Stone died after prolonged battle with COPD. The condition can be debilitating.
Show Caption
Hide Caption
Health officials warn of highest whooping cough cases in a decade
The Centers for Disease Control and Prevention is sounding the alarm about a spike in whooping cough cases in the United States.
Straight Arrow News
Sly Stone, an icon of funk music, has died at the age of 82 following a prolonged battle with COPD, a chronic lung condition that can block airflow and cause difficulty breathing.
"It is with profound sadness that we announce the passing of our beloved dad, Sly Stone of Sly and the Family Stone," a statement shared with USA TODAY on June 9 reads. "After a prolonged battle with COPD and other underlying health issues, Sly passed away peacefully, surrounded by his three children, his closest friend, and his extended family."
The statement continued: "While we mourn his absence, we take solace in knowing that his extraordinary musical legacy will continue to resonate and inspire for generations to come."
Chronic obstructive pulmonary disease, or COPD, describes an ongoing group of lung conditions that includes chronic bronchitis and emphysema. It is the result of damaged lung tissue, which leads to inflammation that irritates the airway and limits airflow. Because such damage usually worsens over time, "COPD mostly affects people who are 50 or older," Dr. Shawn Aaron, senior scientist of the inflammation and chronic disease program at the Ottawa Hospital Research Institute in Canada, previously told USA TODAY.
Here's what medical experts want you to know about COPD.
Funk pioneer Sly Stone, leader of Sly and the Family Stone, dies at 82
What are the symptoms of COPD?
Common symptoms of COPD include wheezing, chest tightness, a painful and persistent cough (with and without accompanying mucus) and fatigue. "Another of the most worrisome features of the disease can be periodic flare-ups, called exacerbations, which can greatly diminish your ability to breathe," Dr. Meilan King Han, pulmonary diseases specialist at University of Michigan Health, previously told USA TODAY. Due to the severity of such episodes, "some COPD patients can end up hospitalized," she added.
COPD also makes people more vulnerable to respiratory infections, such as pneumonia, COVID-19 and tuberculosis. Related complications are why "COPD is a leading cause of death both in America and worldwide," Dr. David Mannino, chief medical officer at the COPD Foundation in Florida, previously told USA TODAY.
At least 15 million adults have some form of COPD, per the U.S. Centers for Disease Control and Prevention, but Mannino said it could be twice that number, because the condition often goes misdiagnosed or undiagnosed.
What causes COPD?
The damaged lung tissue associated with COPD is most often caused by long-term exposure to irritants, such as fumes, dust, chemicals or smoke. This is why "cigarette smoke is the main cause of COPD in high-income countries like the United States," Mannino said. "However, not everyone who smokes will develop COPD symptoms, and not all people with COPD have a history of smoking." Indeed, some 25% of people with COPD have never smoked a cigarette.
COPD can be debilitating. What exactly is it?
"Exposure to outdoor pollution or indoor cooking smoke and fumes is a major cause of COPD," said Aaron, especially in developing countries. He added that some people also develop the condition because of poor early lung development related to premature birth.
Genetic factors, early-life respiratory infections and a history of asthma "can all also contribute to the development of COPD," Han said.
How is COPD treated?
Regardless of what's causing the condition, COPD is treatable. "The mainstays of therapy have historically been inhaled bronchodilators and inhaled steroids," according to Han. Such medications can reduce breathlessness, improve stamina and lower one's risk of flare-ups, Mannino said.
He added that non-pharmacologic therapies are also helpful in reducing symptoms and risk of flare-ups. "These include participating in pulmonary rehabilitation, using oxygen therapy as prescribed and adhering to vaccination guidelines," he said. And you can't overemphasize the importance of quitting smoking, added Aaron.
"By adhering to medication recommendations, avoiding infection and irritating fumes, eating foods that support lung health and strengthening lung tissue by getting plenty of cardiovascular activity," said Mannino, "individuals with COPD can maintain a good quality of life."
Contributing: Daryl Austin and Marco della Cava

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul
Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul

Yahoo

time3 hours ago

  • Yahoo

Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul

Former White House COVID-19 response coordinator Ashish Jha, who served under former President Biden, criticized the decision by Health and Human Services Secretary Robert F. Kennedy Jr. to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel. Kennedy announced the decision in an op-ed for The Wall Street Journal on Monday, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But in an interview with CNN's Wolf Blitzer, Jha pushed back against Kennedy's reasoning. 'Look, what he said in his op-ed was a series of nonsense about a group of individuals, experts …who shape what vaccines, if any, are going to be available to the American people,' Jha said in the interview. 'So obviously this is very concerning,' he continued. 'We'll have to see who he appoints next. But this is a step in the wrong direction.' Jha said he is concerned about what the move foretells about the secretary's agenda on vaccines. Jha pointed to what he characterized as a lackluster response from the secretary to 'the worst measles outbreak of the last 25 years.' He also expressed concern regarding Kennedy's raising questions about vaccines causing autism, which Jha dismissed and said was 'settled science.' 'Then you put this in the middle of all of that,' Jha said, referring to the vaccine panel sweep, 'and what you have is a pretty clear picture that what Secretary Kennedy is trying to do is make sure that vaccines are not readily available to Americans, not just for kids, for the elderly.' 'He could go pretty far with this move, and I really am worried about where we're headed,' Jha continued. He said he's particularly concerned about the effect Kennedy's move will have on kids and whether they will continue having access to certain vaccines in the future. 'Kids rely on vaccines. I'm worried about whether the next generation of kids are going to have access to polio vaccines and measles vaccines. That's where we're heading. That's what we have to push back against.' Kennedy said in his op-ed that he was removing every member of the panel to give the Trump administration an opportunity to appoint its own members. Kennedy has long accused members of the Advisory Committee on Immunization Practices of having conflicts of interest, sparking concern among vaccine advocates that he would seek to install members who are far more skeptical of approving new vaccines. But Jha pushed back against criticism that the panel was all Biden-appointed experts, saying, 'When the Biden administration came in, almost all of the appointees had come from the first Trump administration.' 'That was fine because they were good people,' he said. 'They were experts. Right now, it's the same thing. The people he is firing are experts — like a nurse in Illinois who spent her entire career getting kids vaccinated, cancer doctors from Memorial Sloan Kettering — like these are really good people.' 'And generally, CDC has not worried about when were they appointed. The question is, are they good and are they conflict free.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

UAMS chancellor stepping down after 7 years, returning to faculty
UAMS chancellor stepping down after 7 years, returning to faculty

Yahoo

time5 hours ago

  • Yahoo

UAMS chancellor stepping down after 7 years, returning to faculty

UAMS Chancellor Cam Patterson announces a new $31.7 million grant from the National Institutes of Health on July 10, 2024. (Mary Hennigan/Arkansas Advocate) The leader of Arkansas' largest healthcare system will step down after seven years for personal and medical reasons, the University of Arkansas for Medical Sciences announced Tuesday in a news release. Dr. Cam Patterson became the university's chancellor in June 2018. By giving up his position as chancellor and as UAMS Health CEO, he will return to being a faculty member in the university's cardiology department. Patterson 'is facing medical and personal issues that require more attention than he can give them while serving in the chancellor's position,' according to UAMS' news release. 'The work our team has done at UAMS over the last seven-plus years has been the high point of my career,' Patterson said in the release. 'We have a lot to be proud of and I've been the luckiest guy to be a part of it. I am excited about the opportunity to return to the faculty and engage more deeply in the academic and clinical missions at our institution.' UAMS System President Jay Silveria praised Patterson's leadership tenure in the release. 'Leading UAMS is a demanding task, and I appreciate Dr. Patterson's need to do what he feels is best for himself and his family and for the long-term success of the university,' Silveria said. 'His contributions to UAMS came through unusually restrictive times, and he should be celebrated for his efforts to push the institution forward while navigating a challenging environment.' Patterson 'oversaw both challenges and improvement in the university's economic outlook, despite the myriad issues presented by the COVID-19 pandemic and other unforeseen variables,' the release states. One such challenge was a conflict between state and federal mandates regarding COVID-19 vaccinations. The federal Centers for Medicare and Medicaid Services issued a mandate in November 2021 for health workers to be fully vaccinated or receive exemptions, with noncompliant facilities at risk of losing federal funding. The rule directly conflicted with a 2021 Arkansas law that said COVID-19 vaccination 'shall not be a condition of education, employment, entry, or services from the state or a state agency or entity' unless lawmakers approved an exception. Patterson sought an exemption and defended this decision before a legislative committee. Silveria will name an interim UAMS chancellor 'in the coming weeks' and start a national search for Patterson's permanent successor, the news release states. SUPPORT: YOU MAKE OUR WORK POSSIBLE

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Miami Herald

time5 hours ago

  • Miami Herald

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store